Citations

Mayo Clinic

Clear

9374 citation(s) found for "Ly, Thomas".

Proteomic analysis of mantle-cell lymphoma by protein microarray
Leontovich, Alexey A. , Loegering, David A., Dai, Nga T., Krajnik, Kelly L., Stenson, Mary, Melhem, Mona F., Novak, Anne J. , Ansell, Stephen M. , Ghobrial, Irene M. , McCormick, Daniel , Kaufmann, Scott H. , Witzig, Thomas E.

Blood | January 14, 2005 | Volume: 105 | Issue: 9 | Pages: 3722-3730

10.1182/blood-2004-10-3999 | PMID 15650054 Get It

Abstract Mantle-cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphoma (NHL) that behaves aggressively and remains incurable. In order to understand the pathogenesis of MCL and design new therapies, it is important to accurately analyze molecular changes in pathways dysregulated in MCL. We used antibody microarrays to compare patterns of protein expression between CD19+ purified B lymphocytes from normal tonsil and 7 cases of histologically confirmed MCL. Protein overexpression was defined as a higher than 1.3-fold or 2-fold increase in at least 67% of tumor samples compared with normal B-cell control. Of the polypeptides, 77 were overexpressed using the higher than 1.3-fold cutoff, and 13 were overexpressed using the 2-fold cutoff. These included cell cycle regulators (regulator of chromosome condensation 1 [RCC1], murine double minute 2 [MDM2]), a kinase (citron Rho-interacting kinase [CRIK]), chaperone proteins (heat shock 90-kDa protein [Hsp90], Hsp10), and phosphatase regulators (A-kinase anchor protein 1 [AKAP149], protein phosphatase 5 [PP5], and inhibitor 2). The elevated expression of some of these polypeptides was confirmed by immunoblotting and immunohistochemistry, whereas elevated expression of others could not be confirmed, illustrating the importance of confirmatory studies. This study describes a novel technique that identifies proteins dysregulated in MCL.
PPARγ Staining as a Surrogate for PAX8/PPARγ Fusion Oncogene Expression in Follicular Neoplasms: Clinicopathological Correlation and Histopathological Diagnostic Value
Şahi̇n, Mustafa , Allard, Brandon L., Yates, Martin T. , Powell, J. Gregory, Wang, Xiao-Li, Zhao, Ying , Goellner, John R., Sebo, Thomas J., Grebe, Stefan K., Eberhardt, Norman L., McIver, Bryan, Wang, Xiao-Li, Hay, Ian

The Journal of Clinical Endocrinology & Metabolism | January 10, 2005 | Volume: 90 | Issue: 1 | Pages: 463-468

10.1210/jc.2004-1203 | PMID 15483076 Get It

Abstract The PAX8/PPARγ (PPFP) fusion-oncogene is moderately specific for follicular thyroid carcinomas (FTC). It remains unknown whether this can be translated into improved diagnosis, classification, or outcome prediction. We studied a cohort of well-characterized follicular adenomas (FA), FTC, and Hürthle cell carcinomas (HCC) from patients with complete clinical follow-up, to determine whether PPARγ immunohistochemistry (as a surrogate of PAX8/PPARγ expression) helps to distinguish FA from FTC and to assess its diagnostic accuracy as an adjunct to frozen section. We also correlated PPARγ staining with clinical outcomes to assess its role as a prognostic marker. PPARγ staining was more common in FTC (31 of 54; 57%) than in HCC (one of 23; 4%) or FA (four of 31; 13%) (P < 0.000001). Adjunctive use of PPARγ immunohistochemistry improved diagnostic sensitivity of intraoperative frozen section from 84% to 96% (P < 0.05) but reduced specificity from 100% to 90% (P < 0.05). PPARγ staining was associated with favorable prognostic indicators (female gender, better tumor differentiation, and lesser risk of metastases). PPARγ staining may be helpful in the differential diagnosis of FA, FTC, and HCC, particularly when diagnostic sensitivity of histomorphology is reduced (e.g. during intraoperative frozen section). PPARγ staining also shows an association with favorable prognosis and may have a role in risk stratification.
Physiology Is a Stronger Predictor of Survival than Pathology in Fibrotic Interstitial Pneumonia
Jegal, Yangjin , Kim, Dong Soon, Shim, Tae Sun , Lim, Chae‐Man , Lee, Sang‐Do , Kim, Woo Sung , Lee, Jin Seong , Kitaichi, Masanori, Colby, Thomas V. , Koh, Younsuck , Kim, Won Dong , Travis, William D.

American Journal of Respiratory and Critical Care Medicine | January 7, 2005 | Volume: 171 | Issue: 6 | Pages: 639-644

10.1164/rccm.200403-331oc | PMID 15640368 Get It

Abstract The histopathologic pattern provides the most important prognostic marker for idiopathic interstitial pneumonia; however, studies have suggested that short-term changes in lung function may be more important. We investigated the prognostic factors for fibrotic interstitial pneumonia. The clinical features and follow-up course of 179 patients (131 with idiopathic pulmonary fibrosis and 48 with nonspecific interstitial pneumonia; 41 fibrotic types and 7 cellular) were analyzed retrospectively. The lung function indices improved or stabilized in most patients with fibrotic nonspecific interstitial pneumonia in contrast to the deterioration or stable condition of most patients with idiopathic pulmonary fibrosis. The 5-year survival of patients with fibrotic nonspecific interstitial pneumonia (76.2%) was better than for those with idiopathic pulmonary fibrosis (43.8%) (p = 0.007). Multivariate analysis at the time of presentation revealed that pathologic pattern, age, and diffusion capacity had important prognostic implications. However, after 6 months of follow-up, changes in FVC, initial diffusion capacity, and sex were the only independent prognostic factors, with no additional prognostic information conferred by the histologic diagnosis. Our data confirmed the importance of physiological parameters including short-term change in FVC. However, at the time of diagnosis, histopathology was important for the prediction of prognosis and future change in lung function.
Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors
Milne, Thomas A. , Hughes, Christina M., Lloyd, Ricardo V., Rozenblatt–Rosen, Orit , Schnepp, Robert W. , Krankel, Cynthia, LiVolsi, Virginia A. , Gibbs, Denise , Hua, Xianxin , Hess, Jay L. , Yang, Zhaohai , Dou, Yali , Roeder, Robert G. , Meyerson, Matthew

Proceedings of the National Academy of Sciences | January 7, 2005 | Volume: 102 | Issue: 3 | Pages: 749-754

10.1073/pnas.0408836102 | PMID 15640349 Get It

Mutations in the MEN1 gene are associated with the multiple endocrine neoplasia syndrome type 1 (MEN1), which is characterized by parathyroid hyperplasia and tumors of the pituitary and pancreatic islets. The mechanism by which MEN1 acts as a tumor suppressor is unclear. We have recently shown that menin, the MEN1 protein product, interacts with mixed lineage leukemia (MLL) family proteins in a histone methyltransferase complex including Ash2, Rbbp5, and WDR5. Here, we show that menin directly regulates expression of the cyclin-dependent kinase inhibitors p27 Kip1 and p18 Ink4c . Menin activates transcription by means of a mechanism involving recruitment of MLL to the p27 Kip1 and p18 Ink4c promoters and coding regions. Loss of function of either MLL or menin results in down-regulation of p27 Kip1 and p18 Ink4c expression and deregulated cell growth. These findings suggest that regulation of cyclin-dependent kinase inhibitor transcription by cooperative interaction between menin and MLL plays a central role in menin's activity as a tumor suppressor.
MONITORING INTRAVESICAL THERAPY FOR SUPERFICIAL BLADDER CANCER USING FLUORESCENCE IN SITU HYBRIDIZATION
Kipp, Benjamin R. , Karnes, R. Jeffrey , Brankley, Shannon M., Harwood, Aaron R., Sebo, Thomas J., BLUTE, MICHAEL M., Lieber, Michael M., Zincke, Horst, Halling, Kevin C. , Pankratz, V. Shane

Journal of Urology | January 7, 2005 | Volume: 173 | Issue: 2 | Pages: 401-404

10.1097/01.ju.0000149825.83180.a4 | PMID 15643180 Get It

Ligand Binding Characteristics of the Human Serotonin1A Receptor Heterologously Expressed in CHO Cells
Kalipatnapu, Shanti, Pucadyil, Thomas J. , Chattopadhyay, Amitabha , Harikumar, Kaleeckal G.

Bioscience Reports | December 3, 2004 | Volume: 24 | Issue: 2 | Pages: 101-115

10.1007/s10540-004-7191-1 | PMID 15628665 Get It

The serotonin1A (5-HT1A) receptors are important members of the superfamily of seven transmembrane domain G-protein coupled receptors. They appear to be involved in various behavioral, cognitive and developmental functions. Mammalian cells in culture heterologously expressing membrane receptors represent convenient systems to address problems in receptor biology. We report here the pharmacological characterization of one of the first isolated clones of CHO cells stably expressing the human 5-HT1A receptor using the selective agonist 8-OH-DPAT and antagonist p-MPPF. In addition, we demonstrate that agonist and antagonist binding to the receptor exhibit differential sensitivity to the non-hydrolyzable GTP analogue, GTP-γ-S, as was observed earlier with the native receptor from bovine hippocampus. These results show that the human 5-HT1A receptor expressed in CHO cells displays characteristic features found in the native receptor isolated from bovine hippocampus and promises to be a potentially useful system for future studies of the receptor.
Malignant pheochromocytoma: current status and initiatives for future progress
Eisenhofer, Graeme , Bornstein, Stefan R. , Brouwers, Frederieke M., Cheung, Nai‐Kong V. , Giordano, Thomas J. , Lehnert, Hendrik, Manger, William M., Neumann, Hartmut P.H., Pacák, Karel , Shulkin, Barry L. , Smith, David I, Tischler, Arthur S. , Dahia, Patricia L. M. , Krijger, Ronald R. de , Greene, Lloyd A. , Goldstein, David S. , Maris, John M. , Smith, David I, Young, William F. , Shulkin, Barry L

Endocrine-Related Cancer | December 2, 2004 | Volume: 11 | Issue: 3 | Pages: 423-436

10.1677/erc.1.00829 | PMID 15369446 Get It

Abstract Pheochromocytomas are rare catecholamine-producing neuroendocrine tumors that are usually benign, but which may also present as or develop into a malignancy. Predicting such behavior is notoriously difficult and there are currently no curative treatments for malignant tumors. This report follows from a workshop at the Banbury Conference Center, Cold Spring Harbor, New York, on the 16th–18th November 2003, held to review the state of science and to facilitate future progress in the diagnosis and treatment of malignant pheochromocytoma. The rarity of the tumor and the resulting fragmented nature of studies, typically involving small numbers of patients, represent limiting factors to the development of effective treatments and diagnostic or prognostic markers for malignant disease. Such development is being facilitated by the availability of new genomics-based tools, but for such approaches to succeed ultimately requires comprehensive clinical studies involving large numbers of patients, stringently collected clinical data and tumor samples, and interdisciplinary collaborations among multiple specialist centers. Nevertheless, the well-characterized hereditary basis and the unique functional nature of these neuroendocrine tumors provide a useful framework that offers advantages for establishing the pathways of tumorigenesis and malignancy. Such findings may have relevance for understanding the basis of other more common malignancies where similar frameworks are not available. As the relevant pathways leading to pheochromocytoma are established it should be possible to take advantage of the new generation of drugs being developed to target specific pathways in other malignancies. Again the success of this will require well-designed and coordinated multicenter studies.
Syncope Evaluation in the Emergency Department Study (SEEDS)
Shen, Win K., Decker, Wyatt W., Smars, Peter A., Goyal, Deepi G. , Walker, A, Hodge, David O. , Trusty, Jane M., Brekke, Karen M., Brady, Peter A. , Munger, Thomas M. , Hammill, Stephen C., Frye, Robert L. , Jahangir, Arshad , Gersh, Bernard J.

Circulation | November 9, 2004 | Volume: 110 | Issue: 24 | Pages: 3636-3645

10.1161/01.cir.0000149236.92822.07 | PMID 15536093 Get It

Background— The primary aim and central hypothesis of the study are that a designated syncope unit in the emergency department improves diagnostic yield and reduces hospital admission for patients with syncope who are at intermediate risk for an adverse cardiovascular outcome. Methods and Results— In this prospective, randomized, single-center study, patients were randomly allocated to 2 treatment arms: syncope unit evaluation and standard care. The 2 groups were compared with χ 2 test for independence of categorical variables. Wilcoxon rank sum test was used for continuous variables. Survival was estimated with the Kaplan-Meier method. One hundred three consecutive patients (53 women; mean age 64±17 years) entered the study. Fifty-one patients were randomized to the syncope unit. For the syncope unit and standard care patients, the presumptive diagnosis was established in 34 (67%) and 5 (10%) patients ( P <0.001), respectively, hospital admission was required for 22 (43%) and 51 (98%) patients ( P <0.001), and total patient-hospital days were reduced from 140 to 64. Actuarial survival was 97% and 90% ( P =0.30), and survival free from recurrent syncope was 88% and 89% ( P =0.72) at 2 years for the syncope unit and standard care groups, respectively. Conclusions— The novel syncope unit designed for this study significantly improved diagnostic yield in the emergency department and reduced hospital admission and total length of hospital stay without affecting recurrent syncope and all-cause mortality among intermediate-risk patients. Observations from the present study provide benchmark data for improving patient care and effectively utilizing healthcare resources.
Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia
Gough, David B., Thompson, Geoffrey B. , Crotty, Thomas B., Donohue, John H., Kvols, Larry K., Carney, J. Aidan, Grant, Clive S., Nagorney, David M.

World Journal of Surgery | October 31, 2004 | Volume: 18 | Issue: 4 | Pages: 473-479

10.1007/bf00353739 | PMID 7725731 Get It

AbstractThe etiology, prognosis, and optimal management of primary gastric carcinoids remain controversial. Records of 36 consecutive patients with gastric carcinoid (15 men) were reviewed retrospectively between 1975 and 1990. Follow‐up was complete in 97% of cases. Mean age at diagnosis was 58.4 years (range 24–82 years). The clinical presentations included anemia (72%), pain (69%), and carcinoid syndrome (11%). Associated autoimmune and endocrine abnormalities were common and included atrophic gastritis (67%), pernicious anemia (58%), hypothyroidism (39%), diabetes (19%), Addison's disease (6%), and hyperparathyroidism (6%). Lesions were nonantral in 78%, involving only the corpus in 42%, the fundus in 28%, and only the antrum in 8%; 42% were multiple. Urinary 5‐hydroxyindoleacetic acid (5‐HIAA) and serum gastrin levels were elevated in 17% and 50% of those tested, respectively. Histologic examination revealed that 28% of lesions were ≥2 cm, and 33% had liver metastases on presentation or developed them during follow‐up. Eight patients (22%) died of tumor with a median survival of 39 months. The presence of metastases, atypical histology, serosal involvement, and size > 2 cm were adverse prognostic factors. In patients without hypergastrinemia (n=6), 66% developed metastases, 60% had elevated 5‐HIAA, and 50% died of carcinoid tumor. In sharp contrast, those patients with hypergastrinemia and “typical” gastric carcinoids (n=15), metastases and death did not occur (p<0.003 and p < 0.005, respectively, compared with eugastrinemic patients). In the latter group (hypergastrinemia and typical histology), pernicious anemia was common (73%); solitary lesions and serosal penetration were seen comparatively less often (33% versus 100%, p<0.005 and 0% versus 33%, p<0.05, respectively); and no lesion measured > 2.0 cm compared to 66% in the group without elevated gastrin (p<0.002). No patient with hypergastrinaemia had elevated levels of 5‐HIAA. Overall survival at 5 and 10 years was 58% and 28%, respectively. Survival was 80% at 5 and 10 years in the hypergastrinemic group. Gastric carcinoid tumors that are histologically atypical, large (>2 cm), or present without elevated gastrin are potentially lethal and require aggressive therapy. In contrast, gastric carcinoids with typical histology and hypergastrinemia are rarely lethal, and conservative management with local excision and close observation is appropriate.
Follow-Up Results of a Phase II Study of Ibritumomab Tiuxetan Radioimmunotherapy in Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma and Mild Thrombocytopenia
Schilder, Russell J., Molina, Arturo , Bartlett, Nancy L. , Gordon, Leo I. , Murray, James L. , Spies, Stewart, Wiseman, Gregory A., Witzig, Thomas E. , Wang, Hua , White, Christine A. , Gordon, Leo I , Bartlett, Nancy L

Cancer Biotherapy and Radiopharmaceuticals | October 22, 2004 | Volume: 19 | Issue: 4 | Pages: 478-481

10.1089/cbr.2004.19.478 | PMID 15453962 Get It